Technical 200dma bullish cross, page-396

I don't class CDX as a biotech. It's a medical device come SAAS company which is why it is so attractive. No 10 year FDA cycle, SAAS style growth, protected by patented physical devices. Yes - medical devices still need FDA approval but it much quicker (And, Atcor is the goto benchmark for blood pressre for the FDA!).

The big change happened in 2018. It started as a vision to shift from pure medical devices into consumer and hospital SAAS: big blue oceans.

It's been about two and half years from vision now to launch. It's coming to a head.